GGrantIndex
← Leaderboards

Michael Demetriou

University Of California-Irvine

Google Scholar ↗PubMed ↗ORCID ↗
$19,395,048
Attributed
$22,966,564
Total exposure
14
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY2005–25
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$22,966,564 · 14

By mechanism

R01$11,798,558 · 5
KL2$3,398,612 · 1
U01$3,398,082 · 1
R42$2,857,880 · 2
R41$698,792 · 2
R56$382,396 · 1

Top collaborators

Most similar at University Of California-Irvine

Same institution · by research overlap

Others in their field

Top investigators on “Polysaccharides”

Research focus

PolysaccharidesT-LymphocyteProteinsCell SurfaceSugarImmuneCarbohydratesComplexGlycosylationSignal TransductionAntigensT-Cell ReceptorSurfaceProtein GlycosylationGalactose Binding LectinCellsPathway InteractionsEnvironmentEndocytosisMembrane GlycoproteinsMetabolicAutoimmunityGeneticRegulation

Grant awards (51)

Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy$1,085,460
R42 · FY2025 · CA · contact PI
Maximizing GlyTR pan-cancer immunotherapy by enhancing target density$463,510
R42 · FY2025 · CA · contact PI
Oral N-Acetylglucosamine as Anti-Neuroinflammatory Add-on therapy for Multiple Sclerosis (NANA-MS)$263,892
R34 · FY2025 · AI · contact PI
Institute for Clinical and Translational Science NRSA Postdoctoral Research Training Core$168,352
T32 · FY2025 · TR
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy$908,910
R42 · FY2024 · CA · contact PI
Institutional Career Development Core$740,019
KL2 · FY2023 · TR
Regulation of B cell function in demyelinating disease by N-glycan branching$500,503
R01 · FY2023 · AI · contact PI
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy$400,000
R42 · FY2023 · CA · contact PI
N-glycosylation and Immunotherapy for cancer$673,731
U01 · FY2022 · CA · contact PI
Regulation of B cell function in demyelinating disease by N-glycan branching$500,503
R01 · FY2022 · AI · contact PI
Institutional Career Development Core$438,536
KL2 · FY2022 · TR
Institutional Career Development Core$740,019
KL2 · FY2021 · TR
N-glycosylation and Immunotherapy for cancer$673,731
U01 · FY2021 · CA · contact PI
Regulation of B cell function in demyelinating disease by N-glycan branching$500,503
R01 · FY2021 · AI · contact PI
Cancer Immunotherapy Targeting Tn Antigen$398,178
R41 · FY2021 · CA · contact PI
Institutional Career Development Core$740,019
KL2 · FY2020 · TR
N-glycosylation and Immunotherapy for cancer$683,540
U01 · FY2020 · CA · contact PI
Regulation of B cell function in demyelinating disease by N-glycan branching$500,503
R01 · FY2020 · AI · contact PI
Institutional Career Development Core$740,019
KL2 · FY2019 · TR
N-glycosylation and Immunotherapy for cancer$683,540
U01 · FY2019 · CA · contact PI
Regulation of B cell function in demyelinating disease by N-glycan branching$500,503
R01 · FY2019 · AI · contact PI
O-Glycan-dependent Immunotherapy for Cancer$2,084
R41 · FY2019 · CA · contact PI
N-glycosylation and Immunotherapy for cancer$683,540
U01 · FY2018 · CA · contact PI
Impaired T cell immunity in the Elderly via enhanced N-glycosylation.$461,402
R01 · FY2018 · AI · contact PI
Mechanisms of human immune modulation by oral N-acetylglucosamine$408,738
R01 · FY2018 · AT · contact PI
O-Glycan-dependent Immunotherapy for Cancer$298,530
R41 · FY2018 · CA · contact PI
Impaired T cell immunity in the Elderly via enhanced N-glycosylation.$461,402
R01 · FY2017 · AI · contact PI
Mechanisms of human immune modulation by oral N-acetylglucosamine$408,738
R01 · FY2017 · AT · contact PI
Impaired T cell immunity in the Elderly via enhanced N-glycosylation.$461,402
R01 · FY2016 · AI · contact PI
Mechanisms of human immune modulation by oral N-acetylglucosamine$408,738
R01 · FY2016 · AT · contact PI
Impaired T cell immunity in the Elderly via enhanced N-glycosylation.$461,402
R01 · FY2015 · AI · contact PI
Mechanisms of human immune modulation by oral N-acetylglucosamine$396,477
R01 · FY2015 · AT · contact PI
Impaired T cell immunity in the Elderly via enhanced N-glycosylation.$460,538
R01 · FY2014 · AI · contact PI
Mechanisms of human immune modulation by oral N-acetylglucosamine$407,996
R01 · FY2014 · AT · contact PI
T cell regulation by N-glycosylation$367,806
R01 · FY2014 · AI · contact PI
Human Autoimmunity and Genetic Defects in N-Glycosylation$347,295
R01 · FY2013 · AI · contact PI
T cell regulation by N-glycosylation$346,992
R01 · FY2013 · AI · contact PI
Human Autoimmunity and Genetic Defects in N-Glycosylation$370,594
R01 · FY2012 · AI · contact PI
T cell regulation by N-glycosylation$370,312
R01 · FY2012 · AI · contact PI
T cell regulation by N-glycosylation$54,632
R01 · FY2012 · AI · contact PI
T cell regulation by N-glycosylation$427,034
R01 · FY2011 · AI · contact PI
Human Autoimmunity and Genetic Defects in N-Glycosylation$371,586
R01 · FY2011 · AI · contact PI
Human Autoimmunity and Genetic Defects in N-Glycosylation$376,220
R01 · FY2010 · AI · contact PI
T cell regulation by N-glycosylation$375,805
R01 · FY2010 · AI · contact PI
T cell regulation by N-glycosylation$54,072
R01 · FY2010 · AI · contact PI
Multiple Sclerosis and Genetic Defects in N-Glycosylation$382,396
R56 · FY2009 · AI · contact PI
Regulation of T cell function and Autoimmunity by Mgat5$289,195
R01 · FY2007 · AI · contact PI
Regulation of T cell function and Autoimmunity by Mgat5$297,833
R01 · FY2006 · AI · contact PI
Regulation of T cell function and Autoimmunity by Mgat5$303,834
R01 · FY2005 · AI
Regulation of T cell function and Autoimmunity by Mgat5$303,000
R01 · FY2004 · AI
Regulation of T Cell Function and Autoimmunity by Mgat5$303,000
R01 · FY2003 · AI